Ultimovacs ASA

Oslo Stock Exchange ULTI.OL

Ultimovacs ASA Free Cash Flow Yield on January 14, 2025: -291.01%

Ultimovacs ASA Free Cash Flow Yield is -291.01% on January 14, 2025, a -6,914.03% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Ultimovacs ASA 52-week high Free Cash Flow Yield is -3.54% on February 20, 2024, which is 98.78% above the current Free Cash Flow Yield.
Ultimovacs ASA 52-week low Free Cash Flow Yield is -363.29% on October 09, 2024, which is -24.84% below the current Free Cash Flow Yield.
Ultimovacs ASA average Free Cash Flow Yield for the last 52 weeks is -153.66%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Oslo Stock Exchange: ULTI.OL

Ultimovacs ASA

CEO	Dr. Carlos de Sousa
IPO Date	June 3, 2019
Location	Norway
Headquarters	Ullernchausséen 64
Employees	17
Sector	Health Care
Industries Pharmaceuticals Biotechnology Vaccines

Description

Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.

Key trends

Past 5 years